Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia

International Clinical Psychopharmacology

Volumn 30, Issue 5, 2015, Pages 290-295

  Üçok, Alp ^a   Çikrikçili, Uʇur ^a   Karabulut, Sercan ^a   Salaj, Ada ^a   Öztürk, Meliha ^a   Tabak, Öznur ^a   Durak, Rümeysa ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

clozapine; schizophrenia; treatment resistance

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE; THERAPY DELAY; TREATMENT RESPONSE; ADVERSE EFFECTS; AGE; DELAYED DIAGNOSIS; DRUG EFFECTS; DRUG RESISTANCE; MIDDLE AGED; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DELAYED DIAGNOSIS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84939506089     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000086     Document Type: Review

References (37)

1. Alessi-Severini S, Le Dorze JA, Nguyen D, Honcharik P, Eleff M. (2013). Clozapine prescribing in a Canadian outpatient population. PLoS One 8: e83539
2. Andreasen NC. (1983). The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Iowa: University of Iowa
3. Andreasen NC. (1984). The Scale for the Assessment of PositiveSymptoms (SAPS). Iowa City, Iowa: University of Iowa
4. Cetin M. (2014). Clozaphobia: fear of prescribers of clozapine for treatment of schizophrenia [in Turkish]. Bull Clin Psychopharmac 24: 295-301
5. Gee S, Vergunst F, Howes O, Taylor D. (2014). Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand 130: 16-24
6. Guy W. (1976). Clinical Global Impressions (CGI) ECDEU Assessment Manual for Psychopharmacology NIMH Psychopharmacology Research Branch Superintendent of Documents. Washington, DC: U.S. Government Printing Office. pp. 218-222
7. Gören JL, Meterko M, Williams S, Young GJ, Baker E, Chou CH, et al. (2013). Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatr Serv 64: 527-533
8. Harrison J, Janlöv M, Wheeler AJ. (2010). Patterns of clozapine prescribing in a mental health service in New Zealand. Pharm World Sci 32: 503-511
9. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. (2012). Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 201: 481-485
10. Kane J, Honigfeld G, Singer J, Meltzer H. (1988). Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-796
11. Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. (2014). The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol 29: 63-76
12. Meltzer HY. (2012). Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses 6: 134-144
13. Miyamoto S, Jarskog LF, FleischhackerWW(2014). New therapeutic approaches for treatment-resistant schizophrenia: a look to the future. J Psychiatr Res 58: 1-6
14. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, et al. (2007a). The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 68: 1751-1762
15. Moore TA, Covell NH, Essock SM, Miller AL. (2007b). Real-world antipsychotic treatment practices. Psychiatr Clin North Am 30: 401-416
16. Mundt AP, Aichberger MC, Fakhriddinov S, Fayzirahmanova M, Grohmann R, Heinz A, et al. (2012). Prescription patterns of patients diagnosed with schizophrenia in mental hospitals in Tashkent/Uzbekistan and in four German cities. Pharmacoepidemiol Drug Saf 21: 145-151
17. Najim H, Heath D, Singh P. (2013). Antipsychotic prescribing before clozapine in a community psychiatric hospital: a case note review. Psychiatr Danub 25 (Suppl 2): S165-S170
18. Nielsen J, Nielsen RE, Correll CU. (2012). Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. J Clin Psychopharmacol 32: 678-683
19. Pai NB, Laidlaw M, Vella SC. (2012). Augmentation of clozapine with another pharmacological agent: treatment for refractory schizophrenia in the real world. Acta Psychiatr Scand 126: 40-46
20. Patel MX, Bishara D, Jayakumar S, Zalewska K, Shiers D, Crawford MJ, Cooper SJ. (2014). Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. Eur Neuropsychopharmacol 24: 499-509
21. Paton C, Barnes TR, Cavanagh MR, Taylor D, Lelliott P, POMH-UK project team. (2008). High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 192: 435-439
22. Petrides G, Malur C, Braga RJ, Bailine SH, Schooler NR, Malhotra AK, et al. (2015). Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry 172: 52-58
23. Porcelli S, Balzarro B, Serretti A. (2012). Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 22: 165-182
24. Rajkumar AP, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob KS. (2013). Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 28: 50-56
25. Si TM, Zhang YS, Shu L, Li KQ, Liu XH, Mei QY, et al. (2012). Use of clozapine for the treatment of schizophrenia: findings of the 2006 research on the china psychotropic prescription studies. Clin Psychopharmacol Neurosci 10: 99-104
26. Sinclair D, Adams CE. (2014). Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials. BMC Psychiatry 14: 253
27. Sommer IE, Begemann MJ, Temmerman A, Leucht S. (2012). Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 38: 1003-1011
28. Stahl SM. (2014). Clozapine: is now the time for more clinicians to adopt this orphan?. CNS Spectr 19: 279-281
29. Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. (2014). Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv 65: 186-192
30. Taylor DM, Young C, Paton C. (2003). Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 64: 30-34
31. Tharyan P, Adams CE. (2005). Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 18: CD000076
32. Ucok A, Soygur H. (2010). The Guideline for treatment of Schizophrenia. Ankara: Publication of Psychiatric Association of Turkey
33. Ventura J, Green MF, Shaner A, Liberman R. (1993). Training and quality assurance with the Brief Psychiatric Rating Scale: the drift busters. Int J Methods Psychiatr Res 3: 221-244
34. Warnez S, Alessi-Severini S. (2014). Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 14: 102
35. Wheeler AJ. (2008). Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother 42: 852-860
36. Wheeler AJ, Feetam CL, Harrison J. (2014). Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom. Clin Drug Investig 34: 203-211
37. Xue Q, Xiong B, Feng Y, Yao L, Chen S, Wiang L. (2014). Socioeconomic factors influencing antipsychotic prescription for schizophrenia inpatients in China: a cross-sectional study. Int Clin Psychopharmacol 29: 288-295